Thr102
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr102  -  MCM4 (human)

Site Information
PSSRVEGtPRsGVrG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 486503
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 )
Disease tissue studied:
breast cancer ( 2 ) , leukemia ( 13 ) , acute myelogenous leukemia ( 13 ) , lung cancer ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 ) , non-small cell lung cancer ( 5 , 6 , 7 , 9 , 10 , 11 ) , non-small cell lung adenocarcinoma ( 5 , 6 , 7 , 8 , 9 , 10 , 11 ) , non-small cell large cell lung carcinoma ( 6 , 9 ) , non-small cell squamous cell lung carcinoma ( 8 ) , small-cell lung cancer ( 3 , 4 )
Relevant cell line - cell type - tissue:
A549 (pulmonary) ( 5 ) , Cal-12T (pulmonary) ( 11 ) , Calu-3 (pulmonary) ( 7 ) , DMS153 (pulmonary) ( 10 ) , DMS53 (pulmonary) ( 4 ) , DMS79 (pulmonary) ( 3 ) , HCC15 (pulmonary) ( 8 ) , HCC44 (pulmonary) ( 11 ) , HCC78 (pulmonary) ( 9 ) , HCC827 (pulmonary) ( 7 ) , HeLa (cervical) ( 17 , 21 ) , HMLER ('stem, breast cancer') ( 2 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 2 ) , Jurkat (T lymphocyte) ( 14 , 15 , 16 , 18 , 19 , 20 , 23 ) , K562 (erythroid) ( 12 , 22 ) , KG-1 (myeloid) ( 13 ) , LOU-NH91 (squamous) ( 8 ) , lung ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 ) , NCI-H128 (pulmonary) ( 3 ) , NCI-H1299 (pulmonary) ( 6 ) , NCI-H1355 (pulmonary) ( 5 ) , NCI-H1417 (pulmonary) ( 3 ) , NCI-H1437 (pulmonary) ( 10 , 11 ) , NCI-H1650 (pulmonary) ( 7 ) , NCI-H1666 (pulmonary) ( 11 ) , NCI-H1703 (squamous) ( 8 ) , NCI-H1734 (pulmonary) ( 6 ) , NCI-H1781 (pulmonary) ( 9 ) , NCI-H1792 (pulmonary) ( 5 ) , NCI-H1944 (pulmonary) ( 6 ) , NCI-H1975 (pulmonary) ( 7 ) , NCI-H2073 (pulmonary) ( 8 , 10 ) , NCI-H209 (pulmonary) ( 3 , 10 ) , NCI-H2106 (pulmonary) ( 7 ) , NCI-H2228 (pulmonary) ( 9 ) , NCI-H23 (pulmonary) ( 5 ) , NCI-H2342 (pulmonary) ( 8 ) , NCI-H2405 (pulmonary) ( 11 ) , NCI-H3122 (pulmonary) ( 9 ) , NCI-H358 (pulmonary) ( 6 ) , NCI-H441 (pulmonary) ( 5 ) , NCI-H446 (pulmonary) ( 4 ) , NCI-H460 (pulmonary) ( 6 ) , NCI-H524 (pulmonary) ( 3 ) , NCI-H526 (pulmonary) ( 4 ) , NCI-H661 (pulmonary) ( 9 ) , NCI-H69 (pulmonary) ( 4 ) , NCI-H82 (pulmonary) ( 4 ) , NCI-H838 (pulmonary) ( 10 ) , U2OS (bone cell) [GR (human)] ( 24 )

References 

1

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

2

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

3

Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

4

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

5

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

6

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

7

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

8

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

9

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

10

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

11

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

12

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

13

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

14

Guo A (2011) CST Curation Set: 12058; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

15

Guo A (2011) CST Curation Set: 12061; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

16

Guo A (2011) CST Curation Set: 12062; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

17

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

18

Possemato A (2010) CST Curation Set: 9289; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

19

Possemato A (2010) CST Curation Set: 9291; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

20

Possemato A (2008) CST Curation Set: 5276; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

21

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

22

Stokes M (2008) CST Curation Set: 4609; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

23

Possemato A (2008) CST Curation Set: 3770; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

24

Lowery DM, et al. (2007) Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate. EMBO J 26, 2262-73
17446864   Curated Info